Spero Therapeutics, Inc.
0 products tracked · names used in filings: Spero Therapeutics, Inc.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Utebzi: PDUFA target action date (complicated urinary tract infections (cUTI), including pyelonephritis, in adults with limited or no alternative oral tre)
Spero Therapeutics, Inc. (SPRO); tebipenem pivoxil; status: met; "FDA approval was received in advance of FDA-assigned Prescription Drug User Fee Act (“PDUFA”) date of June 18, 2026."; filed 2026-06-22 · source
tebipenem HBr: PDUFA target action date (complicated urinary tract infections (cUTI), including pyelonephritis)
Spero Therapeutics, Inc. (SPRO); tebipenem pivoxil hydrobromide; NDA; status: set; "…New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 • Spero maintains its cash runway guidance into 2028"; filed 2026-05-13 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.